Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. (Q54526390)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Galatea Kallergi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

author name string

V Georgoulias

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

V Bozionelou

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

S Agelaki

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

M Perraki

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

S Apostolaki

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

K Kalbakis

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

A Xyrafas

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

D Mavroudis

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

publication date

29 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

1744-1750

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22377561 AND SRC:MED&resulttype=core&format=json

24 January 2020

A pooled analysis of bone marrow micrometastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

The basic biology of HER2.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS020

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54526390&oldid=1561168208"